Showing 4561-4570 of 8485 results for "".
- New Research Explains Why Women Who Have Been Pregnant Have Better Melanoma Outcomeshttps://practicaldermatology.com/news/new-research-explains-why-women-who-have-been-pregnant-have-better-melanoma-outcomes/2457922/For decades, research has associated female sex and a history of previous pregnancy with better outcomes after a melanoma diagnosis. Now, a research team from Perelman School of Medicine at the University of Pennsylvania says it may have determined the reason for the melanoma-protective effect.</
- FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Formhttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-idp-121-acne-treatment-in-lotion-form/2457925/The FDA has accepted Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.
- Jiangsu Hengrui Medicine and Arcutis Partner for Immune-Mediated Dermatology Therapy Using SHR0302https://practicaldermatology.com/news/jiangsu-hengrui-medicine-and-arcutis-partner-for-immune-mediated-dermatology-therapy-using-shr0302/2457936/Jiangsu Hengrui Medicine Co., Ltd., a fully integrated biopharmaceutical company based in Shanghai, and Arcutis, Inc., a biotechnology company based in Menlo Park, CA, entered into an exclusive option and license agreement for the development and commercialization of topical applications of Hengr
- New AD Yardstick Highlights Treatment Advanceshttps://practicaldermatology.com/news/new-ad-yardstick-highlights-treatment-advances/2457933/Treatment for atopic dermatitis (AD) has changed a lot in the last few years, according to a new yardstick published in Annals of Allergy, Asthma and Immunology. “The Atopic Dermatitis Yardstick
- Scientific First: Researchers Grow Hairy Skin In A Dishhttps://practicaldermatology.com/news/scientific-first-researchers-grow-hairy-skin-in-a-dish/2457934/Indiana University School of Medicine researchers have successfully developed a method to grow hairy skin from mouse pluripotent stem cells—a discovery that could lead to new approaches to model disease and new therapies for the treatment of skin disorders and cancers. This res
- BioPhotas, Inc. Launches the Newest Model of the Celluma Serieshttps://practicaldermatology.com/news/biophotas-inc-launches-the-newest-model-of-the-celluma-series/2457943/BioPhotas, Inc. launched its Celluma HOME, a fourth model in the Celluma Series of light therapy devices. The company says the Celluma HOME specifically addresses the challenges of Baby Boomers who struggle with wrinkles, aches and pain. FDA-cleared for over-the-counter purchase, available at an
- DermTech Receives Health Canada Approval to Market PLA and Non-invasive Biopsy Kithttps://practicaldermatology.com/news/dermtech-receives-health-canada-approval-to-market-pla-and-non-invasive-biopsy-kit/2457937/DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. DermTech Canada will market and sell the PLA, and samples will be processed at DermTech’s c
- Microarray Skin Patch May Help Solve Antibiotic Resistance Crisishttps://practicaldermatology.com/news/microarray-skin-patch-may-help-solve-antibiotic-resistance-crisis/2457939/Skin microarray patches that administer drugs directly into the bloodstream through thousands of individual “microneedles” may help solve the antibiotic resistance crisis. “One of the biggest problems is that the huge majority of the drugs are taken orally. This me
- FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Diseasehttps://practicaldermatology.com/news/fda-approves-bmss-opdivo-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease/2457941/The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce t
- BridgeBio Pharma Appoints Drs. Sanuj Ravindran and Eric Michael David as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programshttps://practicaldermatology.com/news/bridgebio-pharma-appoints-drs-sanuj-ravindran-and-eric-michael-david-as-ceos-in-residence-to-lead-dermatology-and-gene-therapy-programs/2457942/BridgeBio Pharma, a clinical-stage biopharmaceutical company, today announced that it has strengthened its executive leadership team with two key hires who will join the company as CEOs-in-residence. Sanuj Ravindran, MD, will serve as CEO of PellePharm, Inc. and wil